Intracoronary Stenting
Low-Molecular-Weight Heparin Comparable With Unfractionated Heparin
Published in Blood Weekly, December 20th, 2001
Results presented at the 2001 Scientific Sessions of the American Heart Association in Anaheim, California, demonstrated that there were no significant differences in efficacy or safety when enoxaparin, a low-molecular-weight heparin, was administered instead of unfractionated heparin as an adjunct to therapy with the intravenous glycoprotein (GP) IIb-IIIa inhibitor, eptifibatide, in patients undergoing intracoronary stent procedures.
On behalf of the CRUISE study investigators, Deepak L. Bhatt, MD, an interventional cardiologist at the Cleveland Clinic Foundation, presented the results of the first randomized trial comparing enoxaparin and unfractionated heparin in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2001-12-20)
More Articles from Blood Weekly
- Acute Myocardial Infarction
Blood Transfusions May Improve Outcome For Elderly Patients - Sickle Cell Disease
Low-Dose Acenocoumarol May Be Effective Over The Long Term - AIDS and HIV Non-Hodgkin Lymphoma
High-Dose Idarubicin-Based Regimen Effective - Aplastic Anemia
Tumor Necrosis Factor-(alpha) Inhibits Hematopoiesis - Blood Substitute
Recombinant Hemoglobin Safe For Anesthetized Patients - Peripheral Arterial Disease
Low-Dose Radiation Prevents Restenosis In Leg Arteries - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
